Search research articles
Contact Us
Filters
Showing results (111-120 of 161) with videos related to
Page
of 17
Sort By:
Journal of Hepatocellular Carcinoma
|
October 29, 2024
A Phase 1a/1b Study of Fostroxacitabine Bralpamide (Fostrox) Monotherapy in Hepatocellular Carcinoma and Solid Tumor Liver Metastases
Ruth Plummer, Alastair Greystoke, Gregory Naylor, et al.
Advances in Therapy
|
October 17, 2018
Pharmacokinetic Effects and Safety of Olaparib Administered with Endocrine Therapy: A Phase I Study in Patients with Advanced Solid Tumours
Ruth Plummer, Henk M Verheul, Filip Y F L De Vos, et al.
Journal of the National Cancer Institute
|
May 6, 2024
Ataxia telangiectasia and Rad3-related (ATR) inhibitor camonsertib dose optimization in patients with biomarker-selected advanced solid tumors (TRESR study)
Elisa Fontana, Ezra Rosen, Elizabeth K Lee, et al.
Cancer Research Communications
|
May 13, 2026
Early ctDNA dynamics predict response to mosperafenib in BRAF V600-mutant metastatic colorectal cancer
Martha Liliana Serrano-Serrano, Christina Godfried Sie, Oliver Bechter, et al.
The Lancet. Oncology
|
March 25, 2015
Vorinostat in patients with advanced malignant pleural mesothelioma who have progressed on previous chemotherapy (VANTAGE-014): a phase 3, double-blind, randomised, placebo-controlled trial
Lee M Krug, Hedy L Kindler, Hilary Calvert, et al.
European Journal of Cancer (Oxford, England : 1990)
|
March 28, 2024
A three-arm randomised phase II study of the MEK inhibitor selumetinib alone or in combination with paclitaxel in metastatic uveal melanoma
Joseph J Sacco, Richard Jackson, Pippa Corrie, et al.
British Journal of Cancer
|
July 24, 2023
A Phase 1/2A trial of idroxioleic acid: first-in-class sphingolipid regulator and glioma cell autophagy inducer with antitumor activity in refractory glioma
Juanita Lopez, Julia Lai-Kwon, Rhoda Molife, et al.
The Lancet. Oncology
|
April 1, 2019
Patient-reported outcomes in patients with resected, high-risk melanoma with BRAF<sup>V600E</sup> or BRAF<sup>V600K</sup> mutations treated with adjuvant dabrafenib plus trametinib (COMBI-AD): a randomised, placebo-controlled, phase 3 trial
Dirk Schadendorf, Axel Hauschild, Mario Santinami, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 23, 2018
Longer Follow-Up Confirms Relapse-Free Survival Benefit With Adjuvant Dabrafenib Plus Trametinib in Patients With Resected <i>BRAF</i> V600-Mutant Stage III Melanoma
Axel Hauschild, Reinhard Dummer, Dirk Schadendorf, et al.
Clinical and Translational Science
|
May 23, 2026
Safety and Efficacy of HexaBody-DR5/DR5 in Malignant Solid Tumors: Phase 1/2a Results and Translational Insights Into Observed Hepatotoxicity
Marije B Overdijk, Kristin Strumane, Ruth Plummer, et al.
Page
of 17
Search research articles
Search
Showing results (111-120 of 161) with videos related to
Sort By:
Page
of 17
Journal of Hepatocellular Carcinoma
|
October 29, 2024
A Phase 1a/1b Study of Fostroxacitabine Bralpamide (Fostrox) Monotherapy in Hepatocellular Carcinoma and Solid Tumor Liver Metastases
Ruth Plummer, Alastair Greystoke, Gregory Naylor, et al.
Advances in Therapy
|
October 17, 2018
Pharmacokinetic Effects and Safety of Olaparib Administered with Endocrine Therapy: A Phase I Study in Patients with Advanced Solid Tumours
Ruth Plummer, Henk M Verheul, Filip Y F L De Vos, et al.
Journal of the National Cancer Institute
|
May 6, 2024
Ataxia telangiectasia and Rad3-related (ATR) inhibitor camonsertib dose optimization in patients with biomarker-selected advanced solid tumors (TRESR study)
Elisa Fontana, Ezra Rosen, Elizabeth K Lee, et al.
Cancer Research Communications
|
May 13, 2026
Early ctDNA dynamics predict response to mosperafenib in BRAF V600-mutant metastatic colorectal cancer
Martha Liliana Serrano-Serrano, Christina Godfried Sie, Oliver Bechter, et al.
The Lancet. Oncology
|
March 25, 2015
Vorinostat in patients with advanced malignant pleural mesothelioma who have progressed on previous chemotherapy (VANTAGE-014): a phase 3, double-blind, randomised, placebo-controlled trial
Lee M Krug, Hedy L Kindler, Hilary Calvert, et al.
European Journal of Cancer (Oxford, England : 1990)
|
March 28, 2024
A three-arm randomised phase II study of the MEK inhibitor selumetinib alone or in combination with paclitaxel in metastatic uveal melanoma
Joseph J Sacco, Richard Jackson, Pippa Corrie, et al.
British Journal of Cancer
|
July 24, 2023
A Phase 1/2A trial of idroxioleic acid: first-in-class sphingolipid regulator and glioma cell autophagy inducer with antitumor activity in refractory glioma
Juanita Lopez, Julia Lai-Kwon, Rhoda Molife, et al.
The Lancet. Oncology
|
April 1, 2019
Patient-reported outcomes in patients with resected, high-risk melanoma with BRAF<sup>V600E</sup> or BRAF<sup>V600K</sup> mutations treated with adjuvant dabrafenib plus trametinib (COMBI-AD): a randomised, placebo-controlled, phase 3 trial
Dirk Schadendorf, Axel Hauschild, Mario Santinami, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 23, 2018
Longer Follow-Up Confirms Relapse-Free Survival Benefit With Adjuvant Dabrafenib Plus Trametinib in Patients With Resected <i>BRAF</i> V600-Mutant Stage III Melanoma
Axel Hauschild, Reinhard Dummer, Dirk Schadendorf, et al.
Clinical and Translational Science
|
May 23, 2026
Safety and Efficacy of HexaBody-DR5/DR5 in Malignant Solid Tumors: Phase 1/2a Results and Translational Insights Into Observed Hepatotoxicity
Marije B Overdijk, Kristin Strumane, Ruth Plummer, et al.
Page
of 17